NASDAQ$URGN
UroGen Pharma Ltd · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
UroGen reported financial results for Q3 2022, with JELMYTO® net product revenue increasing by 41% year-over-year and FDA authorization received for an extended in-use period of JELMYTO® admixture.
UroGen Pharma reported its Q3 2022 financial results, highlighting a 41% increase in JELMYTO® net product revenue compared to the same period last year, reaching $16.1 million. The FDA authorized an extension of the in-use period for JELMYTO® admixture, and the company is progressing with its UGN-102 Phase 3 pivotal trial.
- JELMYTO® net product revenue reached $16.1 million, a 41% increase year-over-year.
- FDA authorized an extension of the in-use period for JELMYTO® admixture from 8 to 96 hours.
- Full enrollment of ENVISION Phase 3 pivotal trial with UGN-102 expected by the end of November 2022.
- NDA submission for UGN-102 anticipated in the first half of 2024.
Headline financials
Revenue & EPS history
UroGen · Revenue · Quarterly
$16.1M
Revenue by segment
UroGen · $16.1M total across 1 segment · Q3 2022
- JELMYTO$16.1M+41.2%100.0%
Forward guidance
UroGen is focused on advancing its pipeline, particularly UGN-102, and maintaining a disciplined approach to capital preservation.
Tailwinds
- Expected completion of ENVISION Phase 3 trial enrollment by the end of November 2022.
- Potential for UGN-102 to transform bladder cancer treatment.
- Advancing UGN-301 in a Phase 1 clinical trial.
- FDA authorization to extend JELMYTO’s in-use period for the admixture from 8 hours to 96 hours.
- Favorable growth trends in JELMYTO's net product revenues.
Headwinds
- Clinical trial enrollment challenges may impact the expected timing of planned clinical trials.
- Potential safety and other complications in clinical trials.
- Risk of not obtaining regulatory approval within the expected timeframe or at all.
- Complications associated with commercialization activities, including those resulting from the ongoing COVID-19 pandemic.
- Negative effects on UroGen’s business, commercialization, and product development plans caused by COVID-19 or geopolitical events.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-1.5%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-4.5%
Avg return
30 days after
50%
17 / 34 earnings
Positive
+22.0%
Q3 2025
Best reaction
-28.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.2% | +31.3% | +12.6% | |
| Q4 2025 | -12.4% | -5.7% | -12.7% | |
| Q3 2025 | +22.0% | +22.4% | +19.0% | |
| Q1 2025 | +7.1% | -29.6% | -29.7% | |
| Q4 2024 | +1.0% | +12.7% | +2.9% | |
| Q3 2024 | -0.9% | +4.8% | +0.7% | |
| Q2 2024 | +3.0% | +2.0% | -10.1% | |
| Q1 2024 | +1.8% | +3.8% | -0.2% | |
| Q4 2023 | -17.2% | -14.0% | -13.6% | |
| Q3 2023 | -1.5% | +6.0% | +29.6% | |
| Q2 2023 | +7.1% | +8.0% | -20.0% | |
| Q1 2023 | +4.8% | +2.2% | +1.3% | |
| Q4 2022 | -11.7% | -9.1% | +0.0% | |
| Q3 2022 | -18.8% | -17.2% | -27.6% | |
| Q2 2022 | -4.3% | -5.5% | -11.4% | |
| Q1 2022 | -2.7% | -4.0% | +13.1% | |
| Q4 2021 | -1.9% | -4.4% | -17.3% | |
| Q3 2021 | -28.7% | -37.0% | -46.9% | |
| Q2 2021 | -1.1% | -1.8% | +14.1% | |
| Q1 2021 | -16.3% | -2.9% | -4.7% | |
| Q4 2020 | +2.4% | -0.3% | -5.9% | |
| Q3 2020 | +0.3% | -1.9% | -22.8% | |
| Q2 2020 | +4.4% | -0.9% | -7.7% | |
| Q1 2020 | -0.2% | +2.8% | +13.4% | |
| Q4 2019 | +6.8% | +6.8% | -39.5% | |
| Q3 2019 | +8.0% | +9.7% | +37.9% | |
| Q2 2019 | -1.2% | -0.7% | +2.2% | |
| Q1 2019 | +3.6% | +1.9% | -1.7% | |
| Q4 2018 | +4.1% | +3.3% | -3.8% | |
| Q3 2018 | +0.7% | +1.0% | -0.3% | |
| Q2 2018 | -10.0% | -7.1% | -3.7% | |
| Q1 2018 | +1.8% | +6.0% | -9.9% | |
| Q4 2017 | -5.8% | -7.5% | +3.0% | |
| Q3 2017 | -3.9% | -5.2% | -14.2% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro